OncoSec Medical Incorporated (“OncoSec”) has designed “smart” catheter-based devices to perform minimally invasive intratumoral immunotherapy.
The new catheter-based electrodes are designed to be compatible with standard medical instruments which can access deep visceral tumors and are capable of treating the tumor.
These all-in-one devices have the ability to inject a DNA-based agent while deploying electrodes to perform electroporation in a single procedure.
They have an adjustable needle and deep electrode penetration which allows the doctors to treat tumors of varying dimensions to perform minimally invasive intratumoral immunotherapy.
OncoSec is developing ‘smart’ electroporation technology capable of tissue sensing and real-time feedback control of electroporation pulse trains in order to attain optimal gene transfer and minimize electroporation-mediated tissue damage.
The development of minimally-invasive electroporation devices capable of high-efficiency delivery of immunotherapeutic genes into tumors located anywhere in the body is critical in establishing intratumoral EP-mediated gene therapy as a standard therapeutic modality in immuno-oncology.
Tissue sensing, feedback control, and catheter technology are the new advances in intratumoral gene electro-transfer, using ‘smart’ tissue-sensing technology and the development of catheter-based electrodes, enabling treatment of deep and visceral tumors.
OncoSec’s pipeline of novel intratumoral therapies advances can enable access and high-efficiency gene delivery to tumors throughout the body.
For more information, please visit:
http://immuno-oncologynews.com
Comments are closed.